Inquis Medical, a company focused on improving medical devices, just got a big boost. They've raised $40 million in a Series B funding round. The lead investor is Marshall Wace, a globally recognized firm. Existing investors like ShangBay Capital and EnPointe Ventures also chipped in. This money will help Inquis Medical grow and get their Aventus Thrombectomy System ready for sale.

The Aventus system is special because it uses tissue-sensing technology to give doctors real-time info during procedures. This makes the process more precise and safer for patients. Earlier this year, the FDA gave the green light for this system to be used for certain blood issues. The company is also testing it on patients with pulmonary embolism, a serious blood clot condition.

Vahid and Mojgan Saadat, the co-founders, are excited about this funding. They think it shows that investors believe in their technology and team. With this money, they plan to finish their clinical study and start selling the Aventus system next year.

In the U. S. , around 900, 000 people get a dangerous blood clot condition called venous thromboembolism each year. The Aventus system could make treatments safer and more efficient.

Inquis Medical Secures $40 Million to Boost Thrombectomy System

Actions